[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

Authors :: Singh, Simron
Halperin, Daniel M.
Myrehaug, Sten
Herrmann, Ken
Pavel, Marianne
Kunz, Pamela L.
Chasen, Beth
Capdevila, Jaume
Tafuto, Salvatore
Oh, Do-Youn
Yoo, Changhoon
Falk, Stephen
Halfdanarson, Thorvardur Ragnar
Folitar, Ilya
Zhang, Yufen
Santoro, Paola
Aimone, Paola
de Herder, Wouter W.
Ferone, Diego
Source :: Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, pLBA588-LBA588, 6p
Publication Year :: 2024

Full Text Access

Tools